Healthcare / Diagnostics & ResearchTaipei Exchange
$40.00
+0.30 (+0.76%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $55.6M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
50.0x
↑EV/EBITDA
20.2x
↑ROE
3.6%
↑Gross Margin
41.5%
↓Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.3%
FCF CAGR
—
FCF margin
-8.2%
FCF / Net income
-2.32x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $603.1M · net income $21.4M · FCF $-49.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $603.1M | $603.1M | $661.9M | $592.5M | $547.8M |
| Net Income | $21.4M | $21.4M | $54.7M | $28.6M | $25.7M |
| EBITDA | $53.5M | $53.5M | $85.9M | $50.6M | $44.0M |
| EPS | — | — | 2.04 | 1.06 | 0.96 |
| Gross Margin | 41.5% | 41.5% | 42.3% | 40.0% | 41.3% |
| Operating Margin | 2.1% | 2.1% | 7.5% | 3.0% | 3.8% |
| Net Margin | 3.5% | 3.5% | 8.3% | 4.8% | 4.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.07 | 0.11 | 0.01 |
| Current Ratio | 2.48 | 2.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-49.6M | $-49.6M | $55.6M | $61.7M | $43.7M |
| Returns | |||||
| ROE | 3.6% | 3.6% | 9.9% | 6.6% | 7.4% |
| Valuation | |||||
| P/E | 50.00 | 50.00 | 33.68 | 35.02 | 25.04 |
| EV/EBITDA | 20.24 | 20.24 | 20.42 | 18.11 | 13.46 |
| P/B | 1.77 | 1.77 | 3.33 | 2.32 | 1.86 |
| Growth & Yield | |||||
| Revenue Growth | -8.9% | -8.9% | 11.7% | 8.2% | — |
| EPS Growth | — | — | 92.5% | 10.3% | — |
| Dividend Yield | 4.7% | 4.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.5%
Start / end P/E
n/dx → n/dx
EPS bridge
2.04 → n/d
Residual
-28.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.